Phase II study of sorafenib combined with gemcitabine and 5-fluorouracil in patients with metastatic renal cell carcinoma: Preliminary results

被引：0
|
作者：
Hongyun, L. [1 ]
Zhihong, C. [1 ]
Xiangqing, Y. [1 ]
Lu, S. [1 ]
Chuanliang, C. [1 ]
Xinan, S. [1 ]
Lin, S. [1 ]
Jun, G. [1 ]
机构：
[1] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16093
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Gemcitabine plus 5-Fluorouracil in patients with metastatic renal cancer: preliminary results of a phase II study
    Freschi, A
    Sorio, R
    Rupolo, M
    Scalone, S
    Bearz, A
    Cartei, G
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 365 - 365
  • [2] Efficacy of sorafenib in combination with gemcitabine and fluorouracil in metastatic renal-cell carcinoma: Preliminary result of a multicenter phase II study.
    Guo, J.
    Cui, C. L.
    Chen, H.
    Xie, X. D.
    Chen, J.
    Liang, J.
    Li, F.
    Liu, T. S.
    Chi, Z. H.
    Si, L.
    Sheng, X. N.
    Li, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results
    Tomasello, L.
    Sertoli, M. R.
    Rubagotti, A.
    Guglielmini, P.
    Tacchini, L.
    Bedognetti, D.
    Ricci, F.
    Sanguineti, S.
    Cassata, A.
    Boccardo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma
    DeLima, M
    Amato, RJ
    Jackson, A
    Tu, SM
    Banks, M
    Finn, L
    Ellerhorst, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (06) : 365 - 370
  • [5] A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma
    Ryan, CW
    Vogelzang, NJ
    Stadler, WM
    CANCER, 2002, 94 (10) : 2602 - 2609
  • [6] Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma
    Xue, C.
    Huang, Y.
    Huang, P. Y.
    Yu, Q. T.
    Pan, J. J.
    Liu, L. Z.
    Song, X. Q.
    Lin, S. J.
    Wu, J. X.
    Zhang, J. W.
    Zhao, H. Y.
    Xu, F.
    Liu, J. L.
    Hu, Z. H.
    Zhao, L. P.
    Zhao, Y. Y.
    Wu, X.
    Zhang, J.
    Ma, Y. X.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1055 - 1061
  • [7] A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma
    Xue, Cong
    Yu, Qitao
    Pan, Jian-ji
    Sun, Yuanlu
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma - Results of a pilot study
    Chaouche, M
    Pasturaud, AL
    Kamioner, D
    Grandjean, M
    Franiatte, J
    Tourani, JM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (03): : 288 - 289
  • [9] Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma
    George, Saby
    Dreicer, Robert
    Au, Jessie J. L.
    Shen, Tong
    Rini, Brian I.
    Roman, Susan
    Cooney, Matthew M.
    Mekhail, Tarek
    Elson, Paul
    Wientjes, Guillaume M.
    Ganapathi, Ram
    Bukowski, Ronald M.
    CLINICAL GENITOURINARY CANCER, 2008, 6 (02) : 79 - 85
  • [10] A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma
    Bennouna, J
    Delva, R
    Gomez, F
    Lesimple, T
    Geoffrois, L
    Linassier, C
    Chevreau, C
    Douillard, JY
    Négrier, S
    ONCOLOGY, 2003, 64 (01) : 25 - 27
12345